Mirtazapine for the treatment of hot flushes in breast cancer survivors: A prospective pilot trial

Nicoletta Biglia, Franziska Kubatzki, Paola Sgandurra, Riccardo Ponzone, Davide Marenco, Elisa Peano, Piero Sismondi

Research output: Contribution to journalArticle

Abstract

The purposes of the study are to evaluate the efficacy and safety of mirtazapine 30 mg/daily for 12 weeks to reduce hot flushes (HF) in women with previous breast cancer and to assess the influence of the same treatment on sleep quality and other menopausal symptoms. A prospective pilot trial was conducted in 40 breast cancer patients with at least seven HF per day. A HF diary was completed daily; sleep quality and other menopausal symptoms were assessed with the Pittsburgh Sleep Quality Index (PSQI), the Menopause Rating Scale (MRS) and the SF-36 Health Survey. Treatment was never started by 13 out of 40 patients (32.5%) and was interrupted by 7 out of 27 patients (25%) due to of the occurrence of side effects (mostly somnolence). In the remaining 20 patients who completed the three months treatment period, there was a 55.6% (p <0.05) reduction in HF frequency and 61.9% (p <0.05) reduction in HF score as compared to baseline. A significant reduction in the MRS score (32.8%; p <0.05) was observed. Mirtazapine appears to be effective in reducing HF in breast cancer survivors. The more frequent side effect was somnolence. A sizeable compiliance problem has been observed due to the reluctance to take antidepressant drugs and to side effects.

Original languageEnglish
Pages (from-to)490-495
Number of pages6
JournalBreast Journal
Volume13
Issue number5
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Survivors
Breast Neoplasms
Sleep
Menopause
Therapeutics
Health Surveys
Drug-Related Side Effects and Adverse Reactions
Antidepressive Agents
Safety
mirtazapine

Keywords

  • Breast cancer survivors
  • Hot flushes
  • Menopausal symptoms
  • Mirtazapine

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Mirtazapine for the treatment of hot flushes in breast cancer survivors : A prospective pilot trial. / Biglia, Nicoletta; Kubatzki, Franziska; Sgandurra, Paola; Ponzone, Riccardo; Marenco, Davide; Peano, Elisa; Sismondi, Piero.

In: Breast Journal, Vol. 13, No. 5, 09.2007, p. 490-495.

Research output: Contribution to journalArticle

@article{855b1af9769e407db67205e4e0df91a6,
title = "Mirtazapine for the treatment of hot flushes in breast cancer survivors: A prospective pilot trial",
abstract = "The purposes of the study are to evaluate the efficacy and safety of mirtazapine 30 mg/daily for 12 weeks to reduce hot flushes (HF) in women with previous breast cancer and to assess the influence of the same treatment on sleep quality and other menopausal symptoms. A prospective pilot trial was conducted in 40 breast cancer patients with at least seven HF per day. A HF diary was completed daily; sleep quality and other menopausal symptoms were assessed with the Pittsburgh Sleep Quality Index (PSQI), the Menopause Rating Scale (MRS) and the SF-36 Health Survey. Treatment was never started by 13 out of 40 patients (32.5{\%}) and was interrupted by 7 out of 27 patients (25{\%}) due to of the occurrence of side effects (mostly somnolence). In the remaining 20 patients who completed the three months treatment period, there was a 55.6{\%} (p <0.05) reduction in HF frequency and 61.9{\%} (p <0.05) reduction in HF score as compared to baseline. A significant reduction in the MRS score (32.8{\%}; p <0.05) was observed. Mirtazapine appears to be effective in reducing HF in breast cancer survivors. The more frequent side effect was somnolence. A sizeable compiliance problem has been observed due to the reluctance to take antidepressant drugs and to side effects.",
keywords = "Breast cancer survivors, Hot flushes, Menopausal symptoms, Mirtazapine",
author = "Nicoletta Biglia and Franziska Kubatzki and Paola Sgandurra and Riccardo Ponzone and Davide Marenco and Elisa Peano and Piero Sismondi",
year = "2007",
month = "9",
doi = "10.1111/j.1524-4741.2007.00470.x",
language = "English",
volume = "13",
pages = "490--495",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Mirtazapine for the treatment of hot flushes in breast cancer survivors

T2 - A prospective pilot trial

AU - Biglia, Nicoletta

AU - Kubatzki, Franziska

AU - Sgandurra, Paola

AU - Ponzone, Riccardo

AU - Marenco, Davide

AU - Peano, Elisa

AU - Sismondi, Piero

PY - 2007/9

Y1 - 2007/9

N2 - The purposes of the study are to evaluate the efficacy and safety of mirtazapine 30 mg/daily for 12 weeks to reduce hot flushes (HF) in women with previous breast cancer and to assess the influence of the same treatment on sleep quality and other menopausal symptoms. A prospective pilot trial was conducted in 40 breast cancer patients with at least seven HF per day. A HF diary was completed daily; sleep quality and other menopausal symptoms were assessed with the Pittsburgh Sleep Quality Index (PSQI), the Menopause Rating Scale (MRS) and the SF-36 Health Survey. Treatment was never started by 13 out of 40 patients (32.5%) and was interrupted by 7 out of 27 patients (25%) due to of the occurrence of side effects (mostly somnolence). In the remaining 20 patients who completed the three months treatment period, there was a 55.6% (p <0.05) reduction in HF frequency and 61.9% (p <0.05) reduction in HF score as compared to baseline. A significant reduction in the MRS score (32.8%; p <0.05) was observed. Mirtazapine appears to be effective in reducing HF in breast cancer survivors. The more frequent side effect was somnolence. A sizeable compiliance problem has been observed due to the reluctance to take antidepressant drugs and to side effects.

AB - The purposes of the study are to evaluate the efficacy and safety of mirtazapine 30 mg/daily for 12 weeks to reduce hot flushes (HF) in women with previous breast cancer and to assess the influence of the same treatment on sleep quality and other menopausal symptoms. A prospective pilot trial was conducted in 40 breast cancer patients with at least seven HF per day. A HF diary was completed daily; sleep quality and other menopausal symptoms were assessed with the Pittsburgh Sleep Quality Index (PSQI), the Menopause Rating Scale (MRS) and the SF-36 Health Survey. Treatment was never started by 13 out of 40 patients (32.5%) and was interrupted by 7 out of 27 patients (25%) due to of the occurrence of side effects (mostly somnolence). In the remaining 20 patients who completed the three months treatment period, there was a 55.6% (p <0.05) reduction in HF frequency and 61.9% (p <0.05) reduction in HF score as compared to baseline. A significant reduction in the MRS score (32.8%; p <0.05) was observed. Mirtazapine appears to be effective in reducing HF in breast cancer survivors. The more frequent side effect was somnolence. A sizeable compiliance problem has been observed due to the reluctance to take antidepressant drugs and to side effects.

KW - Breast cancer survivors

KW - Hot flushes

KW - Menopausal symptoms

KW - Mirtazapine

UR - http://www.scopus.com/inward/record.url?scp=34548286794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548286794&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.2007.00470.x

DO - 10.1111/j.1524-4741.2007.00470.x

M3 - Article

C2 - 17760671

AN - SCOPUS:34548286794

VL - 13

SP - 490

EP - 495

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 5

ER -